Biohaven Inks License Deal With Bristol Myers For Worldwide Rights To Taldefgrobep Alfa
25/2 13:52
(RTTNews) - Biohaven Pharmaceutical Holding Co. Ltd. (BHVN), on Friday, said that it has acquired worldwide rights to investigational drug Taldefgrobep alfa from Bristol Myers Squibb (BMY), thereby expanding its late-stage product candidates for the treatment of neurologic, neuro...